Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pacific Edge Limited ( (NZ:PEB) ) has shared an announcement.
Pacific Edge said a draft Medicare Local Coverage Determination for urine-based biomarkers in microhematuria explicitly proposes reimbursement for its Cxbladder Triage and Triage Plus tests, making hematuria evaluation a covered benefit for the first time and excluding rival biomarkers from the associated coding article. Management described the move as positioning the company as the first mover and market leader in non-invasive diagnostics for microhematuria patients suspected of bladder cancer, with the higher-priced Triage Plus expected to improve test utility, broaden eligible patients, and materially enhance the economics toward profitability.
The draft policy, issued by Medicare contractor Novitas, could enable direct reimbursement for more than 66 million Medicare beneficiaries once finalized and is expected to guide coverage decisions by commercial insurers and support international adoption, marking a potential commercial inflection point for Pacific Edge. In parallel, the company is bolstering its balance sheet through a NZ$6 million retail offer to New Zealand shareholders, following a NZ$25.4 million placement at NZ$0.17 per share, to fund its strategy of evidence-led expansion in bladder cancer diagnostics and future products beyond bladder cancer.
More about Pacific Edge Limited
Pacific Edge Limited is a New Zealand–headquartered cancer diagnostics company specializing in non-invasive genomic urine tests for bladder cancer detection and surveillance. Its Cxbladder suite, including Triage and Triage Plus, supports risk stratification for patients with hematuria and recurrent urothelial cancer and is offered globally via CLIA-certified laboratories in New Zealand and the United States. Cxbladder has more than twenty-five peer-reviewed publications backing its clinical utility and is included in the American Urological Association’s Microhematuria Guideline, with adoption in the U.S., Australasia, Israel, and markets across Asia and South America.
Average Trading Volume: 540,355
Technical Sentiment Signal: Hold
Current Market Cap: N$177.9M
See more insights into PEB stock on TipRanks’ Stock Analysis page.